Bod Science Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Bod Science.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	48.2%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Bod Science non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

CHIA:BOD - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2023	3	-8	-6	-6	N/A
3/31/2023	4	-7	-5	-5	N/A
12/31/2022	4	-6	-4	-4	N/A
9/30/2022	5	-6	-4	-4	N/A
6/30/2022	5	-5	-4	-4	N/A
3/31/2022	6	-5	-5	-5	N/A
12/31/2021	8	-5	-6	-6	N/A
9/30/2021	8	-5	-6	-6	N/A
6/30/2021	7	-4	-6	-6	N/A
3/31/2021	7	-4	-5	-5	N/A
12/31/2020	7	-5	-5	-5	N/A
9/30/2020	7	-5	-4	-4	N/A
6/30/2020	6	-5	-4	-3	N/A
3/31/2020	4	-6	-5	-4	N/A
12/31/2019	2	-6	-6	-6	N/A
9/30/2019	2	-7	-6	-6	N/A
6/30/2019	1	-8	-7	-6	N/A
3/31/2019	1	-6	-6	-5	N/A
12/31/2018	1	-5	-5	-4	N/A
9/30/2018	1	-4	-4	-4	N/A
6/30/2018	1	-4	-3	-3	N/A
3/31/2018	1	-3	-3	-3	N/A
12/31/2017	1	-3	-2	-2	N/A
9/30/2017	1	-3	-2	-2	N/A
6/30/2017	0	-3	-2	-2	N/A
3/31/2017	0	-3	N/A	-2	N/A
12/31/2016	0	-2	N/A	-1	N/A
9/30/2016	0	-1	N/A	-1	N/A
6/30/2016	0	0	N/A	0	N/A
6/30/2015	0	0	N/A	N/A	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista BOD è superiore al tasso di risparmio ( 2.2% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di BOD cresceranno più velocemente del mercato Australian

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di BOD cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di BOD cresceranno più rapidamente del mercato Australian.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di BOD cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di BOD è previsto essere elevato tra 3 anni

Bod Science Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Bod Australia Limited Provides Revenue Guidance for the Fiscal Year 2022

Recent updates

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

No independent directors

Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.

Bod Science Limited, Annual General Meeting, Nov 27, 2023

Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)

New major risk - Negative shareholders equity

New minor risk - Financial data availability

New major risk - Shareholder dilution

Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd.

No independent directors

No independent directors

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)

Bod Science Limited Announces Company Secretary Changes

Less than half of directors are independent

Bod Australia Limited Provides Statistical Summary from Its Phase 1 Cannabidiol (CBD) Pharmacokinetic (PK) Study

Bod Australia Limited Announces Resignation of Hanno Cappon as Non-Executive Director

Less than half of directors are independent

Bod Australia Limited, Annual General Meeting, Nov 28, 2022

Less than half of directors are independent

Less than half of directors are independent

Bod Australia Limited to Launch a New Medicinal Cannabis Product to the Australian Market in July

Less than half of directors are independent

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Announces Board Changes

Bod Australia Limited Advises That It Has Successfully Enrolled First Patients for Its Australian-Based Planned Phase Iib Clinical Trial

Less than half of directors are independent

Bod Australia Limited Announces First Patients Enrolled for Long-Covid Study Investigating the Efficacy of CBD- Dominant Medicinal Cannabis

Bod Australia Announces Board Changes

First half 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new and inexperienced directors

Bod Australia Limited's Novel Food Application Accepted by UK Food Service Agency

High number of new and inexperienced directors

Bod Australia Limited Announces Ethics Approval Received for Schedule 3 Clinical Trial

Bod Australia Limited Announces Secures Clinical Trial Authorisation from the United Kingdom's Medicines & Healthcare Products Regulatory Agency

High number of new and inexperienced directors

Bod Australia Limited Provides Revenue Guidance for the Fiscal Year 2022

Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)

Bod Australia Limited Launches New CBD -Based Products

Bod Australia Limited Provides Update on New Medicinal Cannabis Product Launch

Chief Financial Officer has left the company

New 90-day low: AU$0.41

Bod Australia Limited Announces the Resignation of Charles Altshuler as Chief Financial Officer, Effective 31 March 2021

New 90-day low: AU$0.42

Bod Australia Limited announced that it expects to receive AUD 8 million in funding

Bod Australia Limited Receives AUD 200,000 Binding Purchase Order from Exclusive Global Partner

New 90-day high: AU$0.58

Bod Australia Limited Announces Strong Growth in Medicinal Cannabis Sales Continues

Bod Australia Limited Launches CBD Products in the Netherlands

Bod Australia Limited Undertakes a Phase I Trial of the Safety Tolerability and Pharmacokinetics of Cannabidiol, Administered in Healthy Volunteers Across Multiple Formulations

New 90-day high: AU$0.51

New 90-day high: AU$0.40

New 90-day high - AU$0.32

Full year earnings released - AU$0.054 loss per share

New 90-day low - AU$0.26

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita